Gastrointestinal Cancer Market Report 2026

The gastrointestinal cancer market size has grown rapidly in recent years. It will grow from $27.05 billion in 2025 to $30.33 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing prevalence of gastrointestinal cancers, expansion of diagnostic imaging capabilities, rising awareness of early cancer detection, growth in oncology drug development, improved access to cancer treatment facilities.

The gastrointestinal cancer market size is expected to see rapid growth in the next few years. It will grow to $47.4 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing investments in personalized oncology, rising adoption of biomarker-based diagnostics, expansion of immuno-oncology pipelines, growing use of minimally invasive diagnostics, increasing healthcare expenditure on cancer care. Major trends in the forecast period include increasing adoption of targeted gi cancer therapies, rising use of molecular diagnostics, growing focus on immunotherapy combinations, expansion of early cancer screening programs, enhanced integration of precision medicine.

The rising adoption of targeted therapies is expected to drive the growth of the gastrointestinal cancer market in the coming years. Targeted therapies are treatments that specifically inhibit cancer cell growth by acting on defined molecular targets, thereby minimizing damage to normal, healthy cells. These therapies are designed to interfere with particular molecular pathways or genetic mutations that drive the disease, particularly in cancer. Unlike traditional treatments such as chemotherapy, which affect both healthy and diseased cells, targeted therapies focus on the unique characteristics of an individual’s condition. In gastrointestinal (GI) cancer, targeted therapies act on specific genes or proteins controlling tumor growth, enabling precise and effective treatment. This approach improves patient outcomes while reducing side effects compared to conventional chemotherapy. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II at the end of Q1 2023, which increased by 5% to 260 by the end of Q2 2023. Therefore, the rising adoption of targeted therapies is fueling the growth of the gastrointestinal cancer market.

Major companies in the gastrointestinal cancer market are focusing on developing advanced treatments, such as monoclonal antibody therapy, to improve survival rates and reduce treatment-related side effects. Monoclonal antibody therapy involves laboratory-produced antibodies that specifically identify and bind to cancer cells, helping the immune system target and eliminate them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-based chemotherapy, receiving approval from the European Commission. It is a first-line treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval makes VYLOY the first therapy in the European Union targeting CLDN18.2, a biomarker present in about 38% of these patients, supported by positive results from the SPOTLIGHT and GLOW clinical trials.

In February 2025, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired IDRx Inc. for approximately $1.15 billion. This acquisition enables GSK to strengthen its immunology and infectious disease pipeline, accelerate the development of innovative therapies, and expand its precision medicine capabilities to address unmet medical needs. IDRx Inc. is a US-based clinical-stage biopharmaceutical company focused on developing precision therapeutics for gastrointestinal stromal tumors (GIST).

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastrointestinal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the gastrointestinal cancer market by increasing costs of imported diagnostic equipment, imaging systems, laboratory reagents, radiation therapy devices, and specialty oncology drugs. Hospitals and oncology centers in North America and Europe are most affected due to reliance on imported high-end medical technologies, while Asia-Pacific faces cost pressures on pharmaceutical imports. These tariffs are increasing treatment costs and procurement timelines. However, they are also supporting local drug manufacturing, regional diagnostic production, and investments in domestic oncology research and development capabilities.

The gastrointestinal cancer market research report is one of a series of new reports that provides gastrointestinal cancer market statistics, including gastrointestinal cancer industry global market size, regional shares, competitors with a gastrointestinal cancer market share, detailed gastrointestinal cancer market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal cancer industry. This gastrointestinal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastrointestinal (GI) cancer encompasses a group of cancers that impact the digestive system, including the esophagus, stomach, liver, pancreas, gallbladder, small intestine, colon, and rectum. These cancers arise when abnormal cells in the GI tract grow uncontrollably. The primary objective of GI cancer treatment is to eliminate or manage the spread of cancer, alleviate symptoms, and enhance quality of life.

The primary forms of gastrointestinal cancer include colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, liver cancer, and others. Colorectal cancer is a malignancy of the colon or rectum, largely influenced by genetic and lifestyle factors, allowing for targeted screening and treatment in gastrointestinal oncology. Diagnosis involves methods such as endoscopy, biopsy, molecular testing, and imaging, while treatment options include chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery, and others. These diagnostics and treatments are utilized by a range of end-users, including hospitals, oncology centers, research institutes, and diagnostic laboratories.

The gastrointestinal cancer market consists of revenues earned by entities by providing services such as genetic counseling and testing, palliative and supportive care, nutrition and dietary support, rehabilitation services, and follow-up and survivorship programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal cancer market includes sales of laparoscopic instruments, robotic surgery systems, pain management medications, and monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.